ClinicalTrials.gg

Program

HS-10374

A development code. Also written as “HS-10374 tablets”, “HS-10374 6mg tablets” and “HS-10374 tablets 1mg”.

In Hansoh Pharmaceutical Group's pipeline, TYK2. Its studies are mostly in Psoriasis · Arthritis, Psoriatic, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Oct 31, 20246 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group64 open or runningphase 3since Oct 31, 2024Aug 24, 2023none ahead
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10374 (TYK2), phase 2, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2023First study: phase 2 study in PsoriasisFirst studyNCT06077331 · 120 planned · China
  2. Aug 24, 2023Phase 1 study in PsoriasisNCT06033742 · 84 enrolled · China
  3. Dec 8, 2023Phase 2 study in Arthritis, PsoriaticNCT06176508 · 160 planned · China
  4. Oct 31, 2024Phase 3 study in PsoriasisNCT06672393 · 375 planned · China
  5. Apr 10, 2025Phase 2 study in PsoriasisNCT06926582 · 305 planned · China
  6. Aug 20, 2025Phase 1 study in PsoriasisNCT07181343 · 18 enrolled · China

TargetBeta

“TYK2”the company's pipeline, read by Claude · source

Other programs on TYK2

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
deucravacitinibruleBristol-Myers Squibbphase 460
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321
D-2570ruleInventisBiophase 313
TQH3906Sino Biopharmaceuticalphase 36
FXS5626Fosun Pharmaphase 33
TYK2 Inhibitorruleusynova-pharmaceuticals-ltdno phase1

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07181343Psoriasis · China1CompletedJun 17, 202518
NCT06926582Psoriasis · China2Not yet recruitingJul 9, 2026305
NCT06672393Psoriasis · China3Not yet recruitingOct 22, 2025375
NCT06176508Arthritis, Psoriatic · China2RecruitingApr 28, 2026160
NCT06077331Psoriasis · China2RecruitingJul 31, 2024120
NCT06033742Psoriasis · China1CompletedMar 24, 202384

How it is read

Names in the registry

  • “HS-10374 tablets”, 2 entries
  • “HS-10374 6mg tablets”, 2 entries
  • “HS-10374”, 1 entry
  • “HS-10374 tablets 1mg”, 1 entry
  • “HS-10374 tablets 5mg”, 1 entry

Codes read as this program: HS10374.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.